Evidence map›Paper›PMID 40725263›Full record

ArticleInternational journal of molecular sciences2025

Molecular Landscape of Metastatic Lung Adenocarcinoma in Bulgarian Patients-A Prospective Study.

George Dimitrov, Vladislav Nankov, Natalia Chilingirova, Zornitsa Kamburova, Savelina Popovska

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

George DimitrovDepartment of Medical Oncology, Medical University of Sofia, University Hospital "Tsaritsa Yoanna", 1527 Sofia, Bulgaria.ORCID 0000-0002-9925-9025
Vladislav NankovCentre of Competence in Personalized Medicine, 3D and Telemedicine, Robotic Assisted and Minimally Invasive Surgery-Leonardo da Vinci, 5800 Pleven, Bulgaria.
Natalia ChilingirovaMedical Oncology Clinic, Heart and Brain Hospital, 5804 Pleven, Bulgaria.
Zornitsa KamburovaCentre of Competence in Personalized Medicine, 3D and Telemedicine, Robotic Assisted and Minimally Invasive Surgery-Leonardo da Vinci, 5800 Pleven, Bulgaria.
Savelina PopovskaCentre of Competence in Personalized Medicine, 3D and Telemedicine, Robotic Assisted and Minimally Invasive Surgery-Leonardo da Vinci, 5800 Pleven, Bulgaria.

Funding

The support of the project BG16RFPR002-1.014-0002-С001 "CENTRE OF COMPETENCE IN PER-SONALIZED MEDICINE, 3D AND TELEMEDICINE, ROBOTIC ASSISTED AND MINIMALLY INVASIVE SURGERY" funded by the PRIDST 2021-2027, co-funded by the EU is greatly acknowledged. BG16RFPR002-1.014-0002-С001
6 · The paper itself

Abstract

Lung adenocarcinoma exhibits a heterogeneous molecular landscape shaped by key oncogenic drivers and tumor suppressor gene alterations. Mutation frequencies vary geographically, influenced by genetic ancestry and environmental factors. However, the molecular profile of lung adenocarcinoma in Bulgarian patients remains largely uncharacterized. We conducted a prospective study of 147 Bulgarian patients with metastatic lung adenocarcinoma, analyzing clinicopathologic features and somatic mutation frequencies using next-generation sequencing. Key mutations and their prevalence were assessed and compared with published data from other populations. The cohort included predominantly male patients (68.0%) with a median age of 67 years.

Indexed as

Adenocarcinoma of LungLung NeoplasmsAdultAgedAged, 80 and overBulgariaErbB ReceptorsFemaleHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedMutationNeoplasm MetastasisProspective StudiesProto-Oncogene Proteins p21(ras)EGFR protein, humanErbB ReceptorsKRAS protein, humanProto-Oncogene Proteins p21(ras)TP53 protein, humanTumor Suppressor Protein p53Bulgarian populationdriver mutationslung adenocarcinomamolecular profiling

Identifiers

PMID40725263
PMCPMC12295933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.